Pharmacotherapy Specialty Recertification Literature Study: Spring Module A-B (L259045)

ACPE Numbers: Various – see listing below
Content Release Date: April 16, 2025
Expiration Dates: April 14, 2026
Activity Type: Application-based
CE Credits: 10 hours (BPS and ACPE)
Activity Fee: $90 (ASHP member); $165 (non-member)

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles.

Module 1A – Infectious Diseases and Critical Care: This module focuses on current literature in infectious diseases and critically ill patients. Topics include antifungal therapeutic drug monitoring, skin antisepsis, bloodstream infections, and stress ulcer prophylaxis.

Module 1B – Guideline Updates: This module focuses on recent guideline publications. Topics include peripheral artery disease, chronic kidney disease, and diabetes-related foot infections.

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

These activities are part of the ASHP professional development program for BCPS recertification approved by the BPS.

Accreditation

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Target Audience

Recertification Credit

Board certified pharmacists are eligible to receive up to 10 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

Learning Activity	ACPE Number	Contact Hours (ACPE and BPS)	Assessment Pass Point
Module 1A: Infectious Diseases and Critical Care	0204-0000-24-940-H01-P	4.0	70%
Module 1B: Guideline Updates	0204-0000-24-941-H01-P	6.0	73%

Articles and Learning Objectives

Module 1A: Infectious Diseases and Critical Care
ACPE #: 0204-0000-25-918-H01-P

This module focuses on current literature in infectious diseases and critically ill patients. Topics include antifungal therapeutic drug monitoring, skin antisepsis, bloodstream infections, and stress ulcer prophylaxis.

McCreary EK, Davis MR, Narayanan N, et al. Utility of triazole antifungal therapeutic drug monitoring: insights from the Society of Infectious Diseases Pharmacists. Endorsed by the Mycoses Study Group Education and Research Consortium. Pharmacotherapy 2023; 43: 1043 - 1050.

Describe the insights and best practices from the Society of Infectious Diseases Pharmacists (SIDP) for triazole antifungal therapeutic drug monitoring.
Develop recommendations for triazole antifungal therapeutic drug monitoring

The PREP-IT Investigators. Skin antisepsis before surgical fixation of extremity fractures. N Engl J Med 2024; 390: 409-420.

Describe the PREP-IT study comparing isopropyl alcohol-based solutions containing iodine povacrylex with chlorhexidine gluconate as preoperative antisepsis for surgical procedures to repair extremity fractures
Develop recommendations for preoperative antisepsis to prevent surgical site infection in adults undergoing surgical procedures to repair extremity fractures

Widmer AF, Atkinson A, Kuster SP, et al. Povidone iodine vs chlorhexidine gluconate in alcohol for preoperative skin antisepsis: a randomized clinical trial. JAMA. 2024;332(7):541-549.

Describe the study by Widmer and colleagues comparing alcohol-based solutions containing povidone iodine or chlorhexidine gluconate as preoperative antisepsis for cardiac or abdominal surgery
Develop recommendations for preoperative antisepsis to prevent surgical site infection in adults undergoing scheduled elective cardiac or abdominal surgery

Kaasch AJ, Lopez-Cortes LE, Rodriguez-Bano J, et al. Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial. Lancet Infect Dis 2024; 24: 523 - 534.

Describe the SABATO study by Kaasch and colleagues of early switching of intravenous to oral antimicrobial therapy for low-risk Staphylococcus aureus bloodstream infection
Develop recommendations for the route of administration of antimicrobial therapy in adults with low-risk Staphylococcus aureus bloodstream infection

Cook D, Deane A, Lauzier F, et al. Stress ulcer prophylaxis during invasive mechanical ventilation. N Engl J Med. 2024;391:9-20

Describe the Reevaluating the Inhibition of Stress Erosions (REVISE) study
Develop recommendations for the use of intravenous pantoprazole in critically ill patients undergoing invasive ventilation

Module 1B: Guideline Updates
ACPE #: 0204-0000-25-919-H01-P

This module focuses on recent guideline publications. Topics include peripheral artery disease, chronic kidney disease, and diabetes-related foot infections.

Gornik, H, Aronow, H. et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024 Jun, 83 (24) 2497–2604. Focus on: Section 5 (Medical therapy and preventive foot care for patients with PAD).

Describe the 2024 multiorganizational guideline from the American College of Cardiology, American Heart Association, and others for the management of lower extremity peripheral artery disease
Develop recommendations for the management of lower extremity peripheral artery disease

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International 2024; 105: S117 - S314. Focus on Chapter 3 (Delaying CKD progression and managing its complications) and Ch.4 (Medication management and drug stewardship in CKD).

Describe the clinical practice guideline for evaluation and management of chronic kidney disease from the Kidney Disease: Improving Global Outcomes (KDIGO) Work Group
Develop recommendations for the management of people with chronic kidney disease

Senneville E, Albalawi Z, van Asten SA, et al. IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023). Clinical Infectious Diseases, 2023; ciad527, https://doi.org/10.1093/cid/ciad527.

Describe the guidelines on the diagnosis and treatment of diabetes-related foot infections from the International Working Group on the Diabetic Foot (IWGDF) and Infectious Diseases Society of America (IDSA)
Develop recommendations for the management of diabetes-related foot infections

Faculty

Full Faculty Bios

Tina Beck, PharmD, MSCR, BCPS
Associate Professor
University of the Incarnate Word
San Antonio, Texas

Dannielle Brown, PharmD, BCPS
Pharmacy Clinical Specialist, Internal Medicine
The Johns Hopkins Hospital
Clinical Assistant Professor
University of Maryland School of Pharmacy
Baltimore, Maryland

Shannon Haar, PharmD, BCPS
Clinical Assistant Professor
Philadelphia College of Pharmacy
Philadelphia, Pennsylvania

Lauren Igneri, PharmD, BCPS, BCCCP
Critical Care Clinical Pharmacy Specialist
Cooper University HealthCare
Camden, New Jersey

Troy Kish, PharmD, BCPS
Associate Professor of Pharmacy Practice
Long Island University College of Pharmacy
Brooklyn, New York

Jessica Robinson, PharmD, BCPS, BCIDP
Associate Professor
University of Charleston School of Pharmacy
Associate Director of Antimicrobial Stewardship
Charleston Area Medical Center
Charleston, West Virginia

Heather Torbic, PharmD, FCCM, BCPS, BCCCP
Medical ICU Clinical Pharmacist
Cleveland Clinic
Cleveland, Ohio

Content Matter Experts

Christopher Betz, PharmD, BCPS, FASHP, FKSHP
Clinical Pharmacist Practitioner – Cardiology/PharmacogenomicsRo
bley Rex VA Medical Center
Adjunct Professor
Louisville, Kentucky

Snehal H. Bhatt, PharmD, AACC, BCPS-AQ Cardiology, FASHP
Professor of Pharmacy Practice Massachusetts College of Pharmacy and Health Sciences
Framingham, Massachusetts

Brooklyn Olumba, PharmD, BCPS
Clinical Pharmacy Specialist, Ambulatory Care
Memorial Hermann Southwest Hospital
Houston, Texas

Reviewers

Field Testers

Jaclyn Amey, PharmD, BCPS
Steven Asbill, PharmD, BCPS
Stephanie Brooks, PharmD, BCPS
William Bryan, PharmD, BCPS
Holly Dean, PharmD, BCPS
Mayur Desai, PharmD, BCPS, CACP, CPP
Milouse Dornevil, PharmD, BCPS, BCNSP
Nanik Hatsakorzian , PharmD, MPH, BCPS
Stacy Hester, RPh, BCPS, CPPS
Stephanie Hoeprich, PharmD, BCPS
Onyedikachi Ibekwe, Pharm.D., BCPS
Sirisha Kandepi, PharmD, BCPS
Emily Kostelic, PharmD BCPS
Noelle Kwan, PharmD, BCPS
Daisy Leong, PharmD, BCPS
Jamie Mahan, PharmD, BCPS
Kristen Mancuso, PharmD, MBA, BCPS
Matthew Morrison, PharmD, BCPS, BCEMP
Casey Motto, PharmD, BCPS
Michael Napoleon, PharmD, BCPS
Jennifer Osborn, PharmD, BCCP, BCPS
Richard H Parrish II, BSPharm, PhD, FCCP, BCPS
Sarah Pfaehler, PharmD, MBA, BCPS
Sarah Providence, PharmD, BCPS, BCCCP
Jocelyn Reynoso, PharmD, BCPS, BCGP, BCSCP
Eileen Rohrbach, PharmD, BCPS
Anna Simmont, PharmD, BCPS, BCPPS
Josephine Varda, PharmD, BCPS
Jacqueline Vardaros, PharmD, BCPS, MBA
Tyler Vest, PharmD, MS, BCPS, BCSCP, FNCAP
Brandy Voight, PharmD
Kathryn Weber, PharmD, BCPS, BCCP
Paul Chin Hung Wong, BSPharm, PharmD, BCPS, BCGP
Jenny Yook, PharmD, BCPS

Relevant Financial Relationship Disclosures

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

The following persons in control of this activity’s content have relevant financial relationships:

Snehal H. Bhatt: Janssen Pharmaceuticals: speaker's bureau; Inc Astra Zeneca, Inc: advisory board

All other persons in control of content do not have any relevant financial relationships with an ineligible company.

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Methods and CE Requirements

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

Complete the attestation statement
Review all content
Complete and pass the assessments
Complete the evaluations

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

Development

These activities were developed by ASHP.

Board Recert

Member

$90.00

Non-Member

$165.00